MedTrace Logo

Recruiting Blood Donor With Allogeneic Natural Killer Cell

NCT02716571 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-07-31

No results posted yet for this study

Summary

This study on manufacture of MG4101 (allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) after Transarterial Chemoembolization(TACE) will be harvested WBC(white blood cell) and plasma from healthy donors, or plasma from healthy donors by leukapheresis or plasmapheresis procedure.

Conditions

  • Healthy Volunteers

Interventions

OTHER

Leukapheresis or Plasmapheresis

Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma. Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE).

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jung-Hwan Yoon, M.D., Ph.D. · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-28
Primary Completion
2017-06-02
Completion
2017-07-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02716571 on ClinicalTrials.gov